According to a new market research report published by Future Market insights, the global Stable Angina Management Market is expected to grow at a CAGR of 8.6% during the forecast period of 2023-2033. 

Stable angina is a type of chest pain that occurs when the heart muscle does not receive enough blood flow and oxygen. It is a common symptom of coronary artery disease, which is caused by the build-up of plaque in the arteries that supply blood to the heart. Stable angina can be managed through lifestyle changes, medications, and medical procedures.

The hospital pharmacies segment is expected to account for the largest share of the distribution channel segment. Hospital pharmacies have access to a wide range of stable angina management products and services, and they are well-equipped to handle complex patient cases. Moreover, the hospital pharmacies segment is expected to grow due to the increasing number of hospital admissions for cardiovascular diseases.

Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16897

North America is the largest market for stable angina management, followed by Europe and Asia-Pacific. North America has a high prevalence of cardiovascular diseases, including stable angina, which is expected to drive the demand for stable angina management products and services in the region. In addition, the region is at the forefront of technological advancements in the healthcare sector.

In conclusion, the global stable angina management market is experiencing significant growth, driven by rising prevalence of cardiovascular diseases and technological advancements in the healthcare sector. The market is expected to continue to grow in the coming years, presenting significant opportunities for stakeholders in the market. However, to realize these opportunities, stakeholders must overcome the challenges facing the market and develop innovative products and services that meet the evolving needs of patients with stable angina.

Key Takeaways from the Market Study

• From 2018 to 2022, the Stable Angina Management market grew at a CAGR of 5.2%.
• The global Stable Angina Management market is expected to grow with a 8.6% CAGR during 2023 to 2033.
• As of 2033, the Stable Angina Management Market is expected to reach US$ 25.1 Billion.
• According to the FMI analysis, the hospital pharmacies segment accounts for the largest market share.
• North America is expected to possess 40% market share for the Stable Angina Management market. 
• The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Stable Angina Management.” says an FMI analyst

Market Competition

Key players in the market include companies such as Competition Deep Dive,  Abbott, AstraZeneca, Bayer AG,  Bristol-Myers Squibb Company,  F. Hoffmann-La Roche Ltd, ALLERGAN, Gilead Sciences, Inc., GlaxoSmithKline plc., Novartis AG, Pfizer Inc. along with healthcare providers and technology companies among other global players.

• In Early 2022, Health Canada granted approval for Corzyna as an additional therapy for patients suffering from stable angina who do not respond well to or cannot tolerate first-line therapies. Corzyna is considered a second-line therapy and is more expensive than the current treatment options for angina, with an annual cost of $2,555. This medication is recommended to be placed under Special Authorization for ClaimSecure groups subscribing to Managed Plans to ensure it is reserved for patients who have tried or are intolerant to more cost-effective options, while it will be fully covered for groups subscribing to Open Formularies.

Corzyna is a new medication that has been found to decrease the occurrence of angina attacks when used with first-line agents like beta-blockers and calcium channel blockers, as compared to the use of first-line therapies alone. In addition, for those who are intolerant to first-line therapy, Corzyna can be added to lower the dose of first-line therapy, thereby reducing the risk of undesirable side effects such as low blood pressure or heart rate.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global Stable Angina Management market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Drug class, End-User, & Region. 

Key Segments Profiled in the Stable Angina Management Industry Survey

Drug Class:

• Beta Blockers
• Calcium Antagonists
• Anti-coagulants
• Antiplatelets

Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa